31 May 2013: ASCO: TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC)

• 11 years ago
• Posted in:Uncategorized
• 0
• Author: Brian Kirby
• Tags: 2013, bk88, ctc, LOC, pres

Antonarakis ES , Giannakakou PA , Kirby BJ , Nicasio LV , Eisenberger MA , Nanus DM , Tagawa ST, TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC), ASCO 2013, Chicago, IL.